Circassia Ltd has appointed Stewart Sharpe to the newly-created position of vice president, commercial operations ahead of the expected launch of its lead allergy programme. The product will enter Phase 3 in the fourth quarter of 2012.
Mr Sharpe was most recently head of commercial and business development at the Astellas Pharma Inc subsidiary OSI Pharmaceuticals/Prosidion. He has also held senior positions at Takeda, Johnson & Johnson, Novartis, Roche and Glaxo Wellcome.
Circassia announced the appointment on 18 September 2012.
Copyright 2012 Evernow Publishing Ltd